Search research articles
Contact Us
Filters
Showing results (211-220 of 273) with videos related to
Page
of 28
Sort By:
Heart (British Cardiac Society)
|
November 9, 2022
Impact of sodium-glucose cotransporter-2 inhibitors on heart failure and mortality in patients with cancer
Cho-Han Chiang, Cho-Hung Chiang, Cho-Hsien Chiang, et al.
Blood
|
December 17, 2025
PD-1-based combinations before autologous transplant are associated with improved outcomes in classical Hodgkin lymphoma
Sanjal H Desai, Alison J Moskowitz, Reid W Merryman, et al.
Blood Advances
|
September 1, 2019
Dose-escalated interleukin-2 therapy for refractory chronic graft-versus-host disease in adults and children
Jennifer S Whangbo, Haesook T Kim, Nikola Mirkovic, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 15, 2019
Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma
Philippe Armand, Scott Rodig, Vladimir Melnichenko, et al.
Blood Advances
|
March 27, 2026
Impact of Novel Therapies on the Efficacy of Post-Transplantation Brentuximab Vedotin Maintenance in Hodgkin Lymphoma
Ayo Samuel Falade, Robert Redd, Sanjal H Desai, et al.
Blood
|
June 2, 2020
A multicenter phase 1 study of nivolumab for relapsed hematologic malignancies after allogeneic transplantation
Matthew S Davids, Haesook T Kim, Caitlin Costello, et al.
British Journal of Haematology
|
May 21, 2020
Checkpoint blockade treatment sensitises relapsed/refractory non-Hodgkin lymphoma to subsequent therapy
Nicole A Carreau, Philippe Armand, Reid W Merryman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 4, 2018
A Phase I/II Study of Evofosfamide, A Hypoxia-activated Prodrug with or without Bortezomib in Subjects with Relapsed/Refractory Multiple Myeloma
Jacob P Laubach, Chia-Jen Liu, Noopur S Raje, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
October 20, 2019
Early <sup>18</sup>F-FDG PET/CT Response Predicts Survival in Relapsed or Refractory Hodgkin Lymphoma Treated with Nivolumab
Aiping Chen, Fatima-Zohra Mokrane, Lawrence H Schwartz, et al.
Hemasphere
|
November 20, 2025
Outcomes of tafasitamab and lenalidomide in large B-cell lymphoma based on prior CD19-directed CAR T exposure
Mwanasha H Merrill, Robert A Redd, Nicholas Lambert, et al.
Page
of 28
Search research articles
Search
Showing results (211-220 of 273) with videos related to
Sort By:
Page
of 28
Heart (British Cardiac Society)
|
November 9, 2022
Impact of sodium-glucose cotransporter-2 inhibitors on heart failure and mortality in patients with cancer
Cho-Han Chiang, Cho-Hung Chiang, Cho-Hsien Chiang, et al.
Blood
|
December 17, 2025
PD-1-based combinations before autologous transplant are associated with improved outcomes in classical Hodgkin lymphoma
Sanjal H Desai, Alison J Moskowitz, Reid W Merryman, et al.
Blood Advances
|
September 1, 2019
Dose-escalated interleukin-2 therapy for refractory chronic graft-versus-host disease in adults and children
Jennifer S Whangbo, Haesook T Kim, Nikola Mirkovic, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 15, 2019
Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma
Philippe Armand, Scott Rodig, Vladimir Melnichenko, et al.
Blood Advances
|
March 27, 2026
Impact of Novel Therapies on the Efficacy of Post-Transplantation Brentuximab Vedotin Maintenance in Hodgkin Lymphoma
Ayo Samuel Falade, Robert Redd, Sanjal H Desai, et al.
Blood
|
June 2, 2020
A multicenter phase 1 study of nivolumab for relapsed hematologic malignancies after allogeneic transplantation
Matthew S Davids, Haesook T Kim, Caitlin Costello, et al.
British Journal of Haematology
|
May 21, 2020
Checkpoint blockade treatment sensitises relapsed/refractory non-Hodgkin lymphoma to subsequent therapy
Nicole A Carreau, Philippe Armand, Reid W Merryman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 4, 2018
A Phase I/II Study of Evofosfamide, A Hypoxia-activated Prodrug with or without Bortezomib in Subjects with Relapsed/Refractory Multiple Myeloma
Jacob P Laubach, Chia-Jen Liu, Noopur S Raje, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
October 20, 2019
Early <sup>18</sup>F-FDG PET/CT Response Predicts Survival in Relapsed or Refractory Hodgkin Lymphoma Treated with Nivolumab
Aiping Chen, Fatima-Zohra Mokrane, Lawrence H Schwartz, et al.
Hemasphere
|
November 20, 2025
Outcomes of tafasitamab and lenalidomide in large B-cell lymphoma based on prior CD19-directed CAR T exposure
Mwanasha H Merrill, Robert A Redd, Nicholas Lambert, et al.
Page
of 28